Charles R. Cantor

Sequenom, Inc. engages in the provision of early patient management information. It develops and commercializes molecular diagnostic testing services that serve women's health and oncology markets. The company was founded by Hubert Koester and Charles R. Cantor in October 09, 1996 and is headquartered in Burlington, NC.

Cellicon Biotechnologies, Inc. develops pharmaceutical products. It offers technologies for decoding the protein pathway for the cure of human diseases such as diabetes, arthritis, and cancer. The company was founded in 2002 by Timothy Gardner and is headquartered in Boston, MA

Lawrence Berkeley National Laboratory engages on research of environmental studies, nanoscience, and quantitative biology, physics and nuclear energy. The lab is funded by the U.S. Department of Energy and managed by the University of California. It was founded in 1931 by Ernest Orlando Lawrence and is headquartered in Berkeley, CA.

SelectX Pharmaceuticals, Inc. engages in the discovery and development of aminoglycoside therapeutics for unmet medical needs. Its advanced program, development candidate SXP2523, is a next generation aminoglycoside antibiotic for drug resistant gram-negative hospital-acquired infections (HAIs); SXP2523 possesses broad spectrum coverage with potency against Pseudomonas, Klebsiella, Acinetobacter, E. coli, and Staphylococcus. The company was founded by Michael G. Chaparian and Charles R. Cantor in 2002 and is headquartered in Boston, MA.

National Academy of Sciences operates as a private, nongovernmental institution that advises on issues related to science and technology. It provides independent, objective analysis and advice and conducts other activities to solve complex problems and inform public policy decisions. The firm also encourages education and research, recognize outstanding contributions to knowledge, and increase public understanding in matters of science. The company was founded on March 3, 1863 and is headquartered in Washington, DC.

ExSAR has offered drug discovery services to pharmaceutical, biotechnology and academic laboratories since its founding in 1997. In 2005, ExSAR initiated a program of collaborative research relationships to discover new therapeutics for the treatment of protein misfolding disorders. The aim is to become the leading drug developer in a rapidly growing $10+ billion market in metabolic and neurodegenerative disorders. Many of these disorders are characterized by mutations which lead to protein misfolding and instability followed subsequently by protein degradation. Many of these diseases currently lack any effective treatment. ExSAR is now a clinical developmental stage company dedicated to identifying, developing and commercializing small-molecule therapeutics for diseases of protein conformation. ExSAR expects to initiate clinical studies for the treatment of Tay Sachs, Sandhoff and Gaucher Diseases.

The Human BioMolecular Research Institute is a research organization that focuses on advancing scientific knowledge in the fields of biochemistry, molecular biology, and biophysics. The non-profit company is based in San Diego, CA. The institute conducts research on a wide range of topics, including cancer, infectious diseases, and neurodegenerative disorders. The company's goal is to develop new treatments and therapies that can improve human health and well-being.

Retrotope, Inc. operates as clinical-stage pharmaceutical company that develops drugs to treat degenerative diseases. It offers drugs and therapies to treat Parkinson’s, Alzheimer’s, mitochondrial myopathies and retinopathies diseases. The company was founded by Charles R. Cantor, Robert J. Molinari, and Mikhail S. Shchepinov in 2006 and is headquartered in Los Altos, CA.